Concepedia

Author

Gregg Timony

Forma Therapeutics (United States)

Also Known As

G A Timony, G Timony, G. Timony, G.A. Timony, Gregg A Timony, Gregg A. Timony, Gregg Timony

27

Publications

1.2K

Citations

13

H-Index

31

Concepts

All Affiliations

Forma Therapeutics (United States)Scripps Research InstituteBristol-Myers Squibb (Switzerland)Biogen (United States)
GT

About

Gregg Timony is an author at Forma Therapeutics (United States) specializing in medicine, pharmacology, and medicinal chemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

447

2

Natural Sciences

5

5

429

3

Biochemistry

4

4

304

4

Biomolecular Engineering

2

2

118

5

Health Sciences

1

1

18

Gregg Timony

×

14

Publications

1.1K

Citations

13

H-Index

YearCitations

Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P <sub>1</sub> ) and receptor‐5 (S1P <sub>5</sub> ) agonist with autoimmune disease‐modifying activity

Fiona L. Scott, Bryan Clemons, Jennifer L. Brooks,

British Journal of Pharmacology

2016

296

Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

Srinivas Rao Kasibhatla, Kevin Hong, Marco A. Biamonte,

Journal of Medicinal Chemistry

2007

125

7‘-Substituted Benzothiazolothio- and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors

Lin Zhang, Junhua Fan, K. NGUYEN VU,

Journal of Medicinal Chemistry

2006

114

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Robert Peach,

The Journal of Clinical Pharmacology

2017

106

Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90

Jean‐Yves Le Brazidec, Adeela Kamal, David J. Busch,

Journal of Medicinal Chemistry

2004

84

Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90

Marco A. Biamonte, Jiandong Shi, Kevin Hong,

Journal of Medicinal Chemistry

2005

72

Antiproliferatiye effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units

Hiroshi Soda, Éric Raymond, Sunil Sharma,

Anti-Cancer Drugs

1998

65

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Jonathan Q. Tran, Jeffrey Hartung, Allan Olson,

Clinical Pharmacology in Drug Development

2017

58

Pharmacokinetics, Pharmacodynamics, Allometry, and Dose Selection of rPSGL-Ig for Phase I Trial

Soo Peang Khor, Kyle P. McCarthy, Michelle DuPont,

Journal of Pharmacology and Experimental Therapeutics

2000

53

Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists

Joshua Wollam, Michelle Solomon, Christiane Villescaz,

Journal of Allergy and Clinical Immunology

2024

48

Page 1